MedPath

Oral VIRAHALT (Novel Immunomodulatory Herbal combination) Compared to standard of care in Subjects with Moderate to Severe COVID-19

Not Applicable
Completed
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2020/09/028133
Lead Sponsor
K Wellness
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients with laboratory-confirmed (PCR) COVID-19 infection

2. Patients with moderate to severe COVID-19 infection (Early warning score >=5)

3. Hospitalized patients in clinical centres

4. Patients with radiology-confirmed pneumonia within the clinical condition of COVID-19 infection including pulmonary opacity

5. Patients with a clinical indication for pneumonia: increased body temperature (defined as a value above >= 36.6�C axillary route, >= 37.2°C oral route or >= 37.8 °C rectal route), dyspnoea, cough and SpO2 <96%

6. Patients aged >=18 years, both genders

7. Patients or LAR able and willing to understand the study, adhere to all study procedures and sign a written Informed Consent Form (ICF) prior to entering the study or with the assistance of the witness

Exclusion Criteria

1. Patients not COVID-19 PCR positive

2. Patients with mild COVID-19 infection

3. Patients who are study subjects in another clinical study for another investigational agent for COVID-19

4. Patients with malignant disease and who are treated for malignant diseases in the last 5 years

5. Patients with severe liver and kidney insufficiency (Hepatic enzymes (AST, ALT, ALP): 6. More than three times normal at baseline will be excluded. Bilirubin: More than 2 at baseline will be excluded. GFR: Less than 60 at baseline will be excluded)

7. Patients who are receiving therapy with another experimental immunomodulatory or immunosuppressive agent

8. Patients aged < 18; female patients who are pregnant or breastfeeding

9. Known allergy to study nutraceutical or any component thereof

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath